# reload+after+2024-01-20 13:45:29.469962
address1§825 Industrial Road
address2§Suite 400
city§San Carlos
state§CA
zip§94070
country§United States
phone§650 260 7120
website§https://www.iovance.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
fullTimeEmployees§503
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Frederick G. Vogt Esq., J.D., Ph.D.', 'age': 49, 'title': 'Interim CEO, President, General Counsel & Corporate Secretary', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1386600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jean-Marc  Bellemin M.B.A.', 'age': 50, 'title': 'CFO, Principal Accounting Officer & Treasurer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 932200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Igor P. Bilinsky', 'age': 50, 'title': 'Chief Operating Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 932200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Friedrich  Graf Finckenstein M.D.', 'age': 56, 'title': 'Chief Medical Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 1058200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sara  Pellegrino', 'title': 'Vice President of Investor Relations & Public Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tracy  Winton', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Howard B. Johnson M.B.A.', 'age': 63, 'title': 'Chief Business Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Ziegler M.B.A.', 'title': 'Executive Vice President of Commercial', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Raj K. Puri M.D., Ph.D.', 'title': 'Executive VP of Regulatory Strategy & Translational Medicine', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian  Shew M.B.A.', 'title': 'Senior VP & Head of Digital and Information Technology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§6
compensationRisk§7
shareHolderRightsRisk§3
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.378
priceToSalesTrailing12Months§3065.9482
currency§USD
dateShortInterest§1702598400
forwardEps§-1.37
pegRatio§0.23
exchange§NGM
quoteType§EQUITY
shortName§Iovance Biotherapeutics, Inc.
longName§Iovance Biotherapeutics, Inc.
firstTradeDateEpochUtc§1287149400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c5aa837d-1163-386d-bcfa-bbff50dd3670
gmtOffSetMilliseconds§-18000000
targetHighPrice§30.0
targetLowPrice§12.0
targetMeanPrice§20.42
targetMedianPrice§19.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§12
quickRatio§3.973
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
